Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.
Pinnetti
Carmela
C
Baroncelli
Silvia
S
Villani
Paola
P
Fantoni
Massimo
M
Tozzi
Valerio
V
De Luca
Andrea
A
Cauda
Roberto
R
Anzidei
Gianfranco
G
Cusato
Maria
M
Regazzi
Mario
M
Floridia
Marco
M
Tamburrini
Enrica
E
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011760:Pyrrolidinones / Q000008:administration & dosage*; D012367:RNA, Viral / Q000097:blood*; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D019562:Viral Load; D014766:Viremia
D019380:Anti-HIV Agents; D063065:Organophosphonates; D011760:Pyrrolidinones; D012367:RNA, Viral; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D000225:Adenine